Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy. The oral EGFR inhibitor sunvozertinib (Zegfrovy) is ...

AstraZeneca has begun selling a Chinese-developed lung cancer drug in the U.S. that some American patients had been flying to ...

Bengaluru: AstraZeneca said on Wednesday the US Food and Drug Administration granted accelerated approval for its treatment ...

The oral, once-daily EGFR inhibitor is now in specialty distribution for patients whose disease progressed after ...

A groundbreaking immunotherapy treatment for rectal cancer, developed through pioneering research at Memorial Sloan Kettering Cancer Center (MSK) with critical early-stage funding from Swim Across ...

The U.S. Food and Drug Administration (FDA) on Thursday granted accelerated approval to AstraZeneca Plc’s AZN Ultomiris ...

AstraZeneca PLC announced that Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) ...

AstraZeneca’s Zegfrovy demonstrated a 46% overall response rate in a trial supporting its accelerated FDA approval, as the ...

ZEGFROVY is now available in the US for post-platinum EGFR exon 20 insertion NSCLC after a 46% response rate in WU-KONG1B.

AstraZeneca has notched another indication to the belt of its rare disease therapy Ultomiris (ravulizumab) through an accelerated US approval in primary immunoglobulin A nephropat ...

The accelerated approval makes Ultomiris, or ravulizumab, the first and only C5 complement inhibitor approved for this use. Novartis' Fabhalta, or iptacopan, is also approved for this indication but ...

The US regulator has granted Ultomiris accelerated approval in a rare kidney disease, but continued approval hinges on a ...